Vericel (VCEL) Net Equity Issued and Repurchased (2010 - 2026)
Vericel (VCEL) posted Net Equity Issued and Repurchased of $2.9 million for Q2 2026, up 82.85% sequentially from $1.6 million in Q1 2026, and up 59.84% YoY from $1.8 million in Q2 2025.
Analysis
Vericel (VCEL) Net Equity Issued and Repurchased (2010 - 2026) Analysis & Trends
Vericel has reported Net Equity Issued and Repurchased for 10 years, with the latest figure at $2.9 million in Q2 2026.
- Quarterly Net Equity Issued and Repurchased rose 59.84% year-over-year to $2.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.2 million (down 70.49% YoY) and the FY2025 annual result came in at $13.9 million, down 43.16% from the prior year.
- Net Equity Issued and Repurchased advanced to $2.9 million in Q2 2026 per VCEL's latest filing, from $1.6 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $9.4 million in Q1 2025 and troughed at $746000.0 in Q2 2022.
- A 5-year average of $3.1 million and a median of $1.6 million in 2026 frame the typical range for Net Equity Issued and Repurchased.
- The sharpest annual moves came in 2024 and 2026: Net Equity Issued and Repurchased soared 423.88% in 2024, then tumbled 83.39% in 2026.
- Over 5 years, Net Equity Issued and Repurchased stood at $829000.0 in 2022, then jumped by 67.19% to $1.4 million in 2023, then jumped by 423.88% to $7.3 million in 2024, then plunged by 82.72% to $1.3 million in 2025, then soared by 127.73% to $2.9 million in 2026.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $2.9 million, $1.6 million, and $1.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 2.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.86 Mn |
| Mar 31, 2026 | 1.56 Mn |
| Dec 31, 2025 | 1.26 Mn |
| Sep 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Mar 31, 2025 | 9.41 Mn |
| Dec 31, 2024 | 7.26 Mn |
| Sep 30, 2024 | 5.80 Mn |
| Jun 30, 2024 | 4.43 Mn |
| Mar 31, 2024 | 7.03 Mn |
| Dec 31, 2023 | 1.39 Mn |
| Sep 30, 2023 | 1.12 Mn |
| Jun 30, 2023 | 1.27 Mn |
| Mar 31, 2023 | 2.23 Mn |
| Sep 30, 2022 | 829,000.00 |
| Jun 30, 2022 | 746,000.00 |
| Mar 31, 2022 | 1.47 Mn |
| Mar 31, 2014 | 5.46 Mn |
| Dec 31, 2013 | 1.59 Mn |
| Sep 30, 2013 | 10.47 Mn |